Monoclonal antibodies (mAbs) have emerged as a promising new drug class for the treatment of multiple myeloma (MM). Daratumumab (DARA), a CD38 mAb, has demonstrated safety, tolerability and activity in a range of clinical trials, both as monotherapy and in combination strategies for MM. The favorable efficacy results in heavily pretreated patients with advanced MM have provided the rationale for the investigation of DARA in a number of ongoing and future phase II and III trials. The general tolerability of mAbs has allowed for widespread investigation and use of DARA among a variety of MM patients, however their use requires special consideration. Infusion-related reactions (IRRs), interference with blood compatibility assays and response assessments are all unique factors related to the use of DARA. This review provides an update of the results from the DARA clinical trials conducted to date, its future plans for investigation, and practical management considerations for the use of DARA in daily practice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167079 | PMC |
http://dx.doi.org/10.1177/2040620716677523 | DOI Listing |
JAMA Netw Open
January 2025
Department of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
Importance: Mental health issues among young people are increasingly concerning. Conventional psychological interventions face challenges, including limited staffing, time commitment, and low completion rates.
Objective: To evaluate the effect of a low-intensity online intervention on young people in Hong Kong experiencing moderate or greater mental distress.
Curr Top Behav Neurosci
January 2025
Black Dog Institute, University of New South Wales, Sydney, Australia.
Anxiety disorders in children lead to substantial impairment in functioning and development. Even the most effective gold standard treatments for childhood anxiety have 50% remission rates, suggesting a critical need to improve current treatments. Optimising exposure, the key component of anxiety treatments, represents a promising way to do so.
View Article and Find Full Text PDFEat Weight Disord
January 2025
Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: Transcranial magnetic stimulation (TMS) has emerged as a promising treatment for various neuropsychiatric conditions, including depression, obsessive-compulsive disorder, and Parkinson's disease. Recent research has focused on evaluating its effectiveness in treating patients with anorexia nervosa (AN). This systematic review and meta-analysis examined the impact of TMS on patients with AN and evaluated any potential adverse effects.
View Article and Find Full Text PDFRadiol Phys Technol
January 2025
Department of Radiotherapy, Sri Shankara Cancer Hospital and Research Centre, 1st Cross, Shankarapuram, Basavanagui, Bengaluru, 560004, Karnataka, India.
This study evaluates the dosimetric impact of arc simulation angular resolution in VMAT-based Single Isocentre Multiple Target (SIMT) SRS, focusing on their dependence on target size, isocentre distance, number of arcs, and arc type. A phantom study analysed angular resolution (0.5°, 1°, 2°) effects on dosimetric accuracy for PTVs of 0.
View Article and Find Full Text PDFDrugs Aging
January 2025
Department of Military and Emergency Medicine, Uniformed Services University, Bethesda, MD, USA.
Background: Untreated low back pain (LBP) in older adults can lead to disability and development of chronicity. Due to the potential development of medical comorbidities and negative risks associated with pharmacological use, chronic LBP management for older adults requires a responsive approach.
Methods: The objective of this study is to evaluate the probability of (1) opioid prescription receipt and (2) opioid-sedative coprescription, in a sample of military-service-connected patients enrolled in the Veterans Health Administration (VHA) or TRICARE, ages 30-85 years, receiving care in three systems: VHA, Military Health System (MHS), and nonfederal (civilian) healthcare facilities.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!